Literature DB >> 6122829

Antiemetic drug combinations in advanced cancer.

T D Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6122829     DOI： 10.1016/s0140-6736(82)92015-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer.

Authors:  Declan Walsh; Mellar Davis; Carla Ripamonti; Eduardo Bruera; Andrew Davies; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-08-17       Impact factor: 3.603

Review 2.  Methodological issues in antiemetic studies.

Authors:  M Aapro
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

3.  Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

Authors:  P J Hesketh; S M Grunberg; J Herrstedt; R de Wit; R J Gralla; A D Carides; A Taylor; J K Evans; K J Horgan
Journal:  Support Care Cancer       Date:  2006-02-01       Impact factor: 3.603

Review 4.  Drug management of pain in cancer patients.

Authors:  C B Tuttle
Journal:  Can Med Assoc J       Date:  1985-01-15       Impact factor: 8.262

5.  The management of symptoms in advanced cancer: experience in a hospital-based continuing care unit.

Authors:  P J Hoskin; G W Hanks
Journal:  J R Soc Med       Date:  1988-06       Impact factor: 5.344

6.  Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.

Authors:  J Carmichael; E M Bessell; A L Harris; A W Hutcheon; P J Dawes; S Daniels; E M Bessel
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.